Aveanna Healthcare Holdings Inc. filings document the public-company disclosures of a home healthcare operator with pediatric and adult care services. Its 8-K reports cover operating and financial results, guidance updates, Regulation FD investor presentations, material-event disclosures, capital-structure matters, and material agreements tied to the company and its common stock.
Proxy and governance filings describe annual meeting matters, board composition, committee service, executive compensation arrangements, employment agreements, stock incentive plan matters, and stockholders agreement provisions, including transfer restrictions and ownership-guideline-related terms. The filing record also includes director transitions and governance disclosures connected to compensation, nominating and corporate governance, and clinical quality and compliance oversight.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an 8-K announcing it issued a press release with financial results for the three and nine-month periods ended September 27, 2025. The press release is provided as Exhibit 99.1 and relates to Item 2.02 (Results of Operations and Financial Condition), with related information also referenced under Item 7.01 (Regulation FD).
The company states the information in this report, including Exhibit 99.1, is “furnished” and not “filed,” which means it is not subject to Section 18 liabilities and will only be incorporated by reference in other filings if specifically stated. The filing is signed by the Chief Accounting Officer as of November 6, 2025.
Aveanna Healthcare (AVAH) — Form 4 insider transaction: On 10/24/2025, Director and 10% Owner Paul R. Vigano reported sales by affiliated entities pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares at $9; JHW Iliad Holdings LLC sold 224,553 shares at $9; and JHW Iliad Holdings II LLC sold 23,538 shares at $9.
Following these trades, reported indirect holdings include 19,292,787 shares via J.H. Whitney VII, L.P.; 15,523,809 via PSA Healthcare Investment Holdings LLC; 3,460,515 via JHW Iliad Holdings LLC; 1,426,034 via PSA Iliad Holdings LLC; and 362,746 via JHW Iliad Holdings II LLC.
Aveanna Healthcare Holdings (AVAH) insider transaction: On October 24, 2025, J.H. Whitney VII, L.P. reported the sale of 1,251,909 shares of common stock at $9.00 per share, coded "S", executed in an underwritten secondary offering.
Following the transaction, beneficial holdings reported include 19,292,787 shares indirectly through J.H. Whitney VII, L.P.; 15,523,809 shares indirectly through PSA Healthcare Investment Holdings LLC; and 1,426,034 shares indirectly through PSA Iliad Holdings LLC. The filing notes that certain affiliated entities may be deemed to share voting and dispositive power over these shares, with customary disclaimers of beneficial ownership beyond pecuniary interest.
Aveanna Healthcare (AVAH): insider sale reported. A 10% owner affiliated with J.H. Whitney disclosed sales on 10/24/2025 at $9 per share pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares; JHW Iliad Holdings LLC sold 224,553 shares; JHW Iliad Holdings II LLC sold 23,538 shares.
Following these transactions, reported indirect beneficial holdings included 19,292,787 shares by J.H. Whitney VII, L.P., 3,460,515 shares by JHW Iliad Holdings LLC, and 362,746 shares by JHW Iliad Holdings II LLC. Additional affiliated entities reported holdings as disclosed.
Aveanna Healthcare Holdings Inc. (AVAH) reported that selling stockholders affiliated with J.H. Whitney Equity Partners VII completed a secondary offering of 10,000,000 shares of common stock at $9.00 per share. The underwriters were led by Jefferies and J.P. Morgan, and the transaction closed on October 23, 2025.
The selling stockholders also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares. Aveanna did not issue any shares in this sale and did not receive proceeds, as all shares were sold by existing holders.
Aveanna Healthcare (AVAH): Form 4 discloses secondary sales by affiliated holders. On October 21, 2025, entities affiliated with the reporting person sold Aveanna common stock in an underwritten secondary offering at $9 per share. The disclosed sales included 8,346,059 shares by J.H. Whitney VII, L.P., 1,497,018 shares by JHW Iliad Holdings LLC, and 156,923 shares by JHW Iliad Holdings II LLC.
Following these transactions, the filing lists beneficial ownership positions such as 20,544,696 shares for J.H. Whitney VII, L.P., 15,523,809 shares for PSA Healthcare Investment Holdings LLC, 3,685,068 shares for JHW Iliad Holdings LLC, and 386,284 shares for JHW Iliad Holdings II LLC.
Aveanna Healthcare Holdings (AVAH) reported insider transactions on a Form 4 tied to an underwritten secondary sale by J.H. Whitney–affiliated entities on October 21, 2025. Reported sales included 8,346,059 shares by J.H. Whitney VII, L.P., 1,497,018 shares by JHW Iliad Holdings LLC, and 156,923 shares by JHW Iliad Holdings II LLC, each at $9 per share.
Following the transactions, reported indirect beneficial holdings included 20,544,696 shares for J.H. Whitney VII, L.P., 3,685,068 shares for JHW Iliad Holdings LLC, and 386,284 shares for JHW Iliad Holdings II LLC. Additional reported indirect holdings showed 15,523,809 shares by PSA Healthcare Investment Holdings LLC and 1,426,034 shares by PSA Iliad Holdings LLC.
Aveanna Healthcare (AVAH): insider sale reported. A reporting person affiliated with J.H. Whitney disclosed that J.H. Whitney VII, L.P. sold 8,346,059 shares of Aveanna common stock at $9 per share on 10/21/2025 in an underwritten secondary offering.
Following the transaction, 20,544,696 shares were reported as beneficially owned indirectly by J.H. Whitney VII, L.P. Additional indirect holdings were listed as 15,523,809 shares by PSA Healthcare Investment Holdings LLC and 1,426,034 shares by PSA Iliad Holdings LLC. The filing notes shared voting and dispositive power across related entities as described in the ownership structure.
Aveanna Healthcare Holdings Inc. announced a secondary offering by selling stockholders of 10,000,000 shares of common stock at $9.00 per share. The company will not receive any proceeds from these sales; proceeds go to the selling stockholders. Underwriters have a 30‑day option to purchase up to 1,500,000 additional shares.
The pricing implies an aggregate public offering of $90,000,000, with underwriting discounts of $4,050,000 and proceeds to selling stockholders of $85,950,000. Aveanna’s common stock trades on Nasdaq as AVAH. Shares outstanding were 208,259,393 as of June 28, 2025.
Aveanna also provided preliminary, unaudited Q3 results: revenue of $616–$624 million, net income of $11–$15 million, and Adjusted EBITDA of $77–$81 million, each described as growth over the prior year’s third quarter. Delivery of shares is expected on or about October 23, 2025.
Aveanna Healthcare Holdings (AVAH) announced a secondary offering in which the Selling Stockholders are offering 10,000,000 shares of common stock. The company stated it will not receive any proceeds from these sales. The underwriters have a 30‑day option to purchase up to 1,500,000 additional shares at the public offering price, less underwriting discounts and commissions.
The company included a preliminary third‑quarter update: revenue is expected at $616–$624 million (up 21.0%–22.6% year over year), net income at $11–$15 million (up 125.7%–135.0%), and Adjusted EBITDA at $77–$81 million (up 61.0%–69.3%). These figures are unaudited and subject to completion of financial closing procedures. A 90‑day lock‑up applies to the company, Selling Stockholders, directors and officers, subject to customary exceptions.
Shares outstanding were 208,911,373 as of October 15, 2025; this is a baseline figure, not the amount being offered.